ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 217 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 0.88 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $2,683,000 | -53.8% | 40,469 | -46.6% | 0.17% | -56.7% |
| Q4 2020 | $5,812,000 | +75.1% | 75,752 | -1.8% | 0.40% | +71.1% |
| Q3 2020 | $3,320,000 | +1.7% | 77,108 | +1.9% | 0.23% | +1.8% |
| Q2 2020 | $3,266,000 | +47.6% | 75,635 | -1.7% | 0.23% | +36.5% |
| Q1 2020 | $2,213,000 | -47.1% | 76,924 | +16.7% | 0.17% | -32.7% |
| Q4 2019 | $4,181,000 | +9.3% | 65,926 | -51.4% | 0.25% | +4.6% |
| Q3 2019 | $3,824,000 | +1.0% | 135,699 | -5.0% | 0.24% | -1.2% |
| Q2 2019 | $3,786,000 | -45.1% | 142,887 | -62.0% | 0.24% | -45.1% |
| Q1 2019 | $6,895,000 | +25.2% | 375,754 | -15.3% | 0.44% | +15.3% |
| Q4 2018 | $5,506,000 | -37.6% | 443,375 | -3.7% | 0.38% | -26.3% |
| Q3 2018 | $8,826,000 | -14.3% | 460,423 | -39.2% | 0.51% | +2.0% |
| Q2 2018 | $10,297,000 | +97.2% | 757,137 | +4.5% | 0.50% | +105.7% |
| Q1 2018 | $5,221,000 | +98.8% | 724,228 | +1.5% | 0.24% | +129.0% |
| Q4 2017 | $2,626,000 | – | 713,722 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |